The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.
During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumour. aCGH RGCC can help clinicians to understand more about a patient’s genes, giving them a powerful tool in the fight against cancer.
Test details
Sample type
Whole peripheral blood sample
Analysis period
Approx. 2–3 weeks
Cancer type
Applicable for all cancer types
Final results
3-4 weeks after sample delivery
Sample size
10-15 ml peripheral whole blood
Price*
725 €
* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.
